Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study

Adam J. Paulsen; Karen J. Cruickshanks; Alex Pinto; Carla R. Schubert; Dayna S. Dalton; Mary E. Fischer; Barbara E.K. Klein; Ronald Klein; Michael Y. Tsai; Ted S. Tweed

doi:10.1002/lary.27847

Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study

Adam J. Paulsen, Karen J. Cruickshanks, Alex Pinto, Carla R. Schubert, Dayna S. Dalton, Mary E. Fischer, Barbara E.K. Klein, Ronald Klein, Michael Y. Tsai, Ted S. Tweed

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objective: Hearing impairment (HI) is common in aging adults. Aldosterone, insulin-like growth factor (IGF1), and brain-derived neurotrophic factor (BDNF) have been identified as potentially protective of hearing. The present study aims to investigate these relationships. Methods: The Epidemiology of Hearing Loss Study is a longitudinal population-based study of aging in Beaver Dam, Wisconsin, that began in 1993. Baseline for the present investigation is the 1998 to 2000 phase. Follow-up exams occurred approximately every 5 years, with the most recent occurring from 2013 to 2016. Hearing was measured by pure-tone audiometry. HI was defined as a pure tone average (PTA) > 25 decibels hearing level in either ear. Change in PTA was the difference between follow-up examinations and baseline. Baseline serum samples were used to measure biomarkers in 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the effect of biomarker levels in the lowest quintile (Q1) versus the highest (Q5) on incident HI and PTA change. Results: There were 1,088 participants (69.3% women) at risk of HI included in analyses. The mean baseline age was 63.8 years (standard deviation = 7.0). The 16-year incidence of HI was 54.9% and was higher in men (61.1%) than women (52.1%). In age- and sex-adjusted models, aldosterone (HR = 1.06, 95% CI = 0.82–1.37), IGF1 (HR = 0.92, 95% CI = 0.71–1.19), and BDNF (HR = 0.86, 95% CI = 0.66–1.12) levels were not associated with risk of HI. PTA change was similarly not affected by biomarker levels. Conclusion: Aldosterone, IGF1, and BDNF were not associated with decreased risk of age-related hearing loss in this study. Level of Evidence: 2b. Laryngoscope, 129:2178–2183, 2019.

Original language	English (US)
Pages (from-to)	2178-2183
Number of pages	6
Journal	Laryngoscope
Volume	129
Issue number	9
DOIs	https://doi.org/10.1002/lary.27847
State	Published - Sep 2019

Bibliographical note

Funding Information:
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging, the National Eye Institute, or Research to Prevent Blindness. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

Funding Information:
This study was supported by the National Institute on Aging, award number R37AG011099 (K.J.C.); the National Eye Institute, grant U10EY06594 (B.E.K.K., R.K.); and an unrestricted grant from Research to Prevent Blindness. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Publisher Copyright:
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Keywords

Epidemiology
aldosterone
audiology
brain-derived neurotrophic factor
insulin-like growth factor
neuroprotective
risk factors
sensorineural hearing loss

Access

10.1002/lary.27847

OpenUrl availability

Full text

Cite this

@article{62f0323f586e41d8aa77cf14f00f2f28,

title = "Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study",

abstract = "Objective: Hearing impairment (HI) is common in aging adults. Aldosterone, insulin-like growth factor (IGF1), and brain-derived neurotrophic factor (BDNF) have been identified as potentially protective of hearing. The present study aims to investigate these relationships. Methods: The Epidemiology of Hearing Loss Study is a longitudinal population-based study of aging in Beaver Dam, Wisconsin, that began in 1993. Baseline for the present investigation is the 1998 to 2000 phase. Follow-up exams occurred approximately every 5 years, with the most recent occurring from 2013 to 2016. Hearing was measured by pure-tone audiometry. HI was defined as a pure tone average (PTA) > 25 decibels hearing level in either ear. Change in PTA was the difference between follow-up examinations and baseline. Baseline serum samples were used to measure biomarkers in 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the effect of biomarker levels in the lowest quintile (Q1) versus the highest (Q5) on incident HI and PTA change. Results: There were 1,088 participants (69.3% women) at risk of HI included in analyses. The mean baseline age was 63.8 years (standard deviation = 7.0). The 16-year incidence of HI was 54.9% and was higher in men (61.1%) than women (52.1%). In age- and sex-adjusted models, aldosterone (HR = 1.06, 95% CI = 0.82–1.37), IGF1 (HR = 0.92, 95% CI = 0.71–1.19), and BDNF (HR = 0.86, 95% CI = 0.66–1.12) levels were not associated with risk of HI. PTA change was similarly not affected by biomarker levels. Conclusion: Aldosterone, IGF1, and BDNF were not associated with decreased risk of age-related hearing loss in this study. Level of Evidence: 2b. Laryngoscope, 129:2178–2183, 2019.",

keywords = "Epidemiology, aldosterone, audiology, brain-derived neurotrophic factor, insulin-like growth factor, neuroprotective, risk factors, sensorineural hearing loss",

author = "Paulsen, {Adam J.} and Cruickshanks, {Karen J.} and Alex Pinto and Schubert, {Carla R.} and Dalton, {Dayna S.} and Fischer, {Mary E.} and Klein, {Barbara E.K.} and Ronald Klein and Tsai, {Michael Y.} and Tweed, {Ted S.}",

note = "Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging, the National Eye Institute, or Research to Prevent Blindness. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. Funding Information: This study was supported by the National Institute on Aging, award number R37AG011099 (K.J.C.); the National Eye Institute, grant U10EY06594 (B.E.K.K., R.K.); and an unrestricted grant from Research to Prevent Blindness. The authors have no other funding, financial relationships, or conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2019 The American Laryngological, Rhinological and Otological Society, Inc.",

year = "2019",

month = sep,

doi = "10.1002/lary.27847",

language = "English (US)",

volume = "129",

pages = "2178--2183",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study

AU - Paulsen, Adam J.

AU - Cruickshanks, Karen J.

AU - Pinto, Alex

AU - Schubert, Carla R.

AU - Dalton, Dayna S.

AU - Fischer, Mary E.

AU - Klein, Barbara E.K.

AU - Klein, Ronald

AU - Tsai, Michael Y.

AU - Tweed, Ted S.

N1 - Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging, the National Eye Institute, or Research to Prevent Blindness. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. Funding Information: This study was supported by the National Institute on Aging, award number R37AG011099 (K.J.C.); the National Eye Institute, grant U10EY06594 (B.E.K.K., R.K.); and an unrestricted grant from Research to Prevent Blindness. The authors have no other funding, financial relationships, or conflicts of interest to disclose. Publisher Copyright: © 2019 The American Laryngological, Rhinological and Otological Society, Inc.

PY - 2019/9

Y1 - 2019/9

N2 - Objective: Hearing impairment (HI) is common in aging adults. Aldosterone, insulin-like growth factor (IGF1), and brain-derived neurotrophic factor (BDNF) have been identified as potentially protective of hearing. The present study aims to investigate these relationships. Methods: The Epidemiology of Hearing Loss Study is a longitudinal population-based study of aging in Beaver Dam, Wisconsin, that began in 1993. Baseline for the present investigation is the 1998 to 2000 phase. Follow-up exams occurred approximately every 5 years, with the most recent occurring from 2013 to 2016. Hearing was measured by pure-tone audiometry. HI was defined as a pure tone average (PTA) > 25 decibels hearing level in either ear. Change in PTA was the difference between follow-up examinations and baseline. Baseline serum samples were used to measure biomarkers in 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the effect of biomarker levels in the lowest quintile (Q1) versus the highest (Q5) on incident HI and PTA change. Results: There were 1,088 participants (69.3% women) at risk of HI included in analyses. The mean baseline age was 63.8 years (standard deviation = 7.0). The 16-year incidence of HI was 54.9% and was higher in men (61.1%) than women (52.1%). In age- and sex-adjusted models, aldosterone (HR = 1.06, 95% CI = 0.82–1.37), IGF1 (HR = 0.92, 95% CI = 0.71–1.19), and BDNF (HR = 0.86, 95% CI = 0.66–1.12) levels were not associated with risk of HI. PTA change was similarly not affected by biomarker levels. Conclusion: Aldosterone, IGF1, and BDNF were not associated with decreased risk of age-related hearing loss in this study. Level of Evidence: 2b. Laryngoscope, 129:2178–2183, 2019.

AB - Objective: Hearing impairment (HI) is common in aging adults. Aldosterone, insulin-like growth factor (IGF1), and brain-derived neurotrophic factor (BDNF) have been identified as potentially protective of hearing. The present study aims to investigate these relationships. Methods: The Epidemiology of Hearing Loss Study is a longitudinal population-based study of aging in Beaver Dam, Wisconsin, that began in 1993. Baseline for the present investigation is the 1998 to 2000 phase. Follow-up exams occurred approximately every 5 years, with the most recent occurring from 2013 to 2016. Hearing was measured by pure-tone audiometry. HI was defined as a pure tone average (PTA) > 25 decibels hearing level in either ear. Change in PTA was the difference between follow-up examinations and baseline. Baseline serum samples were used to measure biomarkers in 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the effect of biomarker levels in the lowest quintile (Q1) versus the highest (Q5) on incident HI and PTA change. Results: There were 1,088 participants (69.3% women) at risk of HI included in analyses. The mean baseline age was 63.8 years (standard deviation = 7.0). The 16-year incidence of HI was 54.9% and was higher in men (61.1%) than women (52.1%). In age- and sex-adjusted models, aldosterone (HR = 1.06, 95% CI = 0.82–1.37), IGF1 (HR = 0.92, 95% CI = 0.71–1.19), and BDNF (HR = 0.86, 95% CI = 0.66–1.12) levels were not associated with risk of HI. PTA change was similarly not affected by biomarker levels. Conclusion: Aldosterone, IGF1, and BDNF were not associated with decreased risk of age-related hearing loss in this study. Level of Evidence: 2b. Laryngoscope, 129:2178–2183, 2019.

KW - Epidemiology

KW - aldosterone

KW - audiology

KW - brain-derived neurotrophic factor

KW - insulin-like growth factor

KW - neuroprotective

KW - risk factors

KW - sensorineural hearing loss

UR - http://www.scopus.com/inward/record.url?scp=85061053851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061053851&partnerID=8YFLogxK

U2 - 10.1002/lary.27847

DO - 10.1002/lary.27847

M3 - Article

C2 - 30698838

AN - SCOPUS:85061053851

SN - 0023-852X

VL - 129

SP - 2178

EP - 2183

JO - Laryngoscope

JF - Laryngoscope

IS - 9

ER -

Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this